BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) of $22.00 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-07-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease · last filed 2012-07-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $22.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $5.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $21.00M, a 200.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $60.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2011 was $24.00M, a 60.00% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2010 was $15.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$19.00M, a 311.11% decline from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2008 was $9.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-06-30 | $22.00M 10-Q · filed 2012-07-25 | $27.00M 10-Q · filed 2012-07-25 | $48.00M derived: sum of 3 quarters · filed 2012-07-25 | $108.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2012-03-31 | $5.00M 10-Q · filed 2012-04-26 | $26.00M derived: sum of 2 quarters · filed 2012-04-26 | $86.00M derived: sum of 3 quarters · filed 2012-04-26 | $55.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $81.00M derived: sum of 2 quarters · filed 2012-02-17 | $50.00M derived: sum of 3 quarters · filed 2012-07-25 | $24.00M 10-K · filed 2012-02-17 |
| 2011-09-30 | $60.00M 10-Q · filed 2011-10-27 | $29.00M derived: sum of 2 quarters · filed 2012-07-25 | $3.00M 10-Q · filed 2011-10-27 | $10.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-06-30 | -$31.00M 10-Q · filed 2012-07-25 | -$57.00M 10-Q · filed 2012-07-25 | -$50.00M derived: sum of 3 quarters · filed 2012-07-25 | -$111.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-03-31 | -$26.00M 10-Q · filed 2012-04-26 | -$19.00M derived: sum of 2 quarters · filed 2012-04-26 | -$80.00M derived: sum of 3 quarters · filed 2012-04-26 | -$40.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2010-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$54.00M derived: sum of 2 quarters · filed 2012-02-17 | -$14.00M derived: sum of 3 quarters · filed 2012-02-17 | $15.00M 10-K · filed 2012-02-17 |
| 2010-09-30 | -$61.00M 10-Q · filed 2011-10-27 | -$21.00M derived: sum of 2 quarters · filed 2011-10-27 | $8.00M 10-Q · filed 2011-10-27 | $21.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $40.00M 10-Q · filed 2011-07-28 | $69.00M 10-Q · filed 2011-07-28 | $82.00M derived: sum of 3 quarters · filed 2012-02-17 | $47.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $29.00M 10-Q · filed 2011-04-28 | $42.00M derived: sum of 2 quarters · filed 2012-02-17 | $7.00M derived: sum of 3 quarters · filed 2012-02-17 | -$24.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$22.00M derived: sum of 2 quarters · filed 2012-02-17 | -$53.00M derived: sum of 3 quarters · filed 2012-02-17 | -$19.00M 10-K · filed 2012-02-17 |
| 2009-09-30 | -$35.00M 10-Q · filed 2010-10-26 | -$66.00M derived: sum of 2 quarters · filed 2010-10-26 | -$32.00M 10-Q · filed 2010-10-26 | -$5.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | -$31.00M 10-Q · filed 2010-07-22 | $3.00M 10-Q · filed 2010-07-22 | $30.00M derived: sum of 3 quarters · filed 2011-02-18 | $78.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | $34.00M 10-Q · filed 2010-04-29 | $61.00M derived: sum of 2 quarters · filed 2011-02-18 | $109.00M derived: sum of 3 quarters · filed 2011-02-18 | $117.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2008-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $75.00M derived: sum of 2 quarters · filed 2011-02-18 | $83.00M derived: sum of 3 quarters · filed 2011-02-18 | $9.00M 10-K · filed 2011-02-18 |
| 2008-09-30 | $48.00M 10-Q · filed 2009-10-22 | $56.00M derived: sum of 2 quarters · filed 2009-10-22 | -$18.00M 10-Q · filed 2009-10-22 | |
| 2008-06-30 | $8.00M 10-Q · filed 2009-07-23 | -$66.00M 10-Q · filed 2009-07-23 | ||
| 2007-12-31 | -$56.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |